keyword
MENU ▼
Read by QxMD icon Read
search

infliximab serum

keyword
https://www.readbyqxmd.com/read/28079601/infliximab-optimization-based-on-therapeutic-drug-monitoring-in-pediatric-ibd
#1
Tatyana Hofmekler, Madeline Bertha, Courtney McCracken, Benadette Martineau, Elizabeth McKinnon, Bess T Schoen, Barbara O McElhanon, Gayathri Tenjarla, Subra Kugathasan, Cary Sauer
BACKGROUND: Infliximab (IFX) is an effective treatment for the management of moderate to severe inflammatory bowel disease (IBD). Low serum IFX levels are associated with the development of antibodies to IFX (ATI) which subsequently associated with clinical relapse and increased morbidity. The purpose of this study is to examine the relationship between dose and interval to IFX level. Secondary goal is to evaluate the relationship between IFX level and ATI in a pediatric IBD population...
June 21, 2016: Journal of Pediatric Gastroenterology and Nutrition
https://www.readbyqxmd.com/read/27989502/profiles-of-serum-cytokine-levels-in-takayasu-arteritis-patients-potential-utility-as-biomarkers-for-monitoring-disease-activity
#2
Natsuko Tamura, Yasuhiro Maejima, Daisuke Tezuka, Chisato Takamura, Shunji Yoshikawa, Takashi Ashikaga, Kenzo Hirao, Mitsuaki Isobe
BACKGROUND: Takayasu arteritis (TA) is an autoimmune arteritis of unknown etiology. Currently, the erythrocyte sedimentation rate (ESR) and serum C-reactive protein (CRP) levels are widely used to monitor disease activity of TA. However, sometimes it is difficult to reflect inflammatory symptoms in either CRP or ESR values, especially in TA patients with immunosuppressive therapies. Therefore, higher-accuracy biomarkers for evaluating disease activity need to be explored. METHODS AND RESULTS: We examined 21 Japanese patients diagnosed with TA; 17 TA patients were treated with prednisone with or without additional immunosuppressive therapies and the remaining 4 patients were treated with infliximab, a human monoclonal anti-tumor necrosis factor (TNF)-α antibody...
December 15, 2016: Journal of Cardiology
https://www.readbyqxmd.com/read/27957480/the-utility-of-infliximab-therapeutic-drug-monitoring-among-patients-with-inflammatory-bowel-disease-and-concerns-for-loss-of-response-a-retrospective-analysis-of-a-real-world-experience
#3
Robert A Mitchell, Constantin Shuster, Neal Shahidi, Cherry Galorport, Mari L DeMarco, Gregory Rosenfeld, Robert A Enns, Brian Bressler
Background. Infliximab (IFX) therapeutic drug monitoring (TDM) allows for objective decision making in patients with inflammatory bowel disease (IBD) and loss of response. Questions remain about whether IFX TDM improves outcomes. Methods. Patients with IBD who had IFX TDM due to concerns for loss of response were considered for inclusion. Serum IFX trough concentration and anti-drug antibody (ADA) concentrations were measured. Patients were grouped by TDM results: group 1, low IFX/high ADA; group 2, low IFX/low ADA; group 3, therapeutic IFX...
2016: Canadian Journal of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/27939407/higher-body-mass-index-and-anti-drug-antibodies-predict-the-discontinuation-of-anti-tnf-agents-in-korean-patients-with-axial-spondyloarthritis
#4
Jiwon Hwang, Hye-Mi Kim, Hyemin Jeong, Jaejoon Lee, Joong Kyong Ahn, Eun-Mi Koh, Eun-Suk Kang, Hoon-Suk Cha
OBJECTIVE: The development of anti-drug antibodies (ADAbs) against tumor necrosis factor (TNF) inhibitors is a likely explanation for the failure of TNF-inhibitors in patients with spondyloarthritis (SpA). Our study determined the existence and clinical implications of ADAbs in axial SpA patients. METHODS: According to the Assessment of SpondyloArthritis International Society classification criteria for axial SpA, patients treated with adalimumab or infliximab were recruited consecutively...
November 15, 2016: Revista Brasileira de Reumatologia
https://www.readbyqxmd.com/read/27936119/anti-tnf-%C3%AE-drugs-differently-affect-the-tnf%C3%AE-stnfr-system-and-monocyte-subsets-in-patients-with-psoriasis
#5
Lara Gibellini, Sara De Biasi, Elena Bianchini, Regina Bartolomeo, Antonella Fabiano, Marco Manfredini, Federica Ferrari, Giuseppe Albertini, Tommaso Trenti, Milena Nasi, Marcello Pinti, Anna Iannone, Carlo Salvarani, Andrea Cossarizza, Giovanni Pellacani
TNF-α has a central role in the development and maintenance of psoriatic plaques, and its serum levels correlate with disease activity. Anti-TNF-α drugs are, however, ineffective in a relevant percentage of patients for reasons that are currently unknown. To understand whether the response to anti-TNF-α drugs is influenced by the production of anti-drug antibodies or by the modulation of the TNFα-TNFα receptor system, and to identify changes in monocyte phenotype and activity, we analysed 119 psoriatic patients who either responded or did not respond to different anti-TNF-α therapies (adalimumab, etanercept or infliximab), and measured plasma levels of TNF-α, TNF-α soluble receptors, drug and anti-drug antibodies...
2016: PloS One
https://www.readbyqxmd.com/read/27931515/autologous-adipose-derived-mesenchymal-stromal-cells-for-the-treatment-of-psoriasis-vulgaris-and-psoriatic-arthritis-a-case-report
#6
Miguel M De Jesus, Jayson S Santiago, Camille V Trinidad, Melvin E See, Kimberly R Semon, Manuel O Fernandez, Francisco S Chung
Psoriasis is a dermatologic disease of immune origins with no definitive cure. We report the Makati Medical Center experience of utilizing autologous mesenchymal stromal cells (MSCs) for one patient with psoriasis vulgaris (PV) and another with psoriatic arthritis (PA). Patients were educated and gave informed consent, according to the principles of the Declaration of Helsinki. The protocol was approved by the Cellular Transplantation Ethics Committee of the Makati Medical Center. Autologous MSCs were cultured from lipoaspirate and expanded in a clean room class 100 facility (Cellular Therapeutics Center, Makati Medical Center)...
November 2016: Cell Transplantation
https://www.readbyqxmd.com/read/27904147/penile-constitutive-nitric-oxide-synthase-expression-in-rats-exposed-to-unpredictable-chronic-mild-stress-role-of-inflammation
#7
T D Şahin, Y Yazır, T Utkan, S S Göçmez, D Bayramgürler
Chronic psychological stress cause erectile dysfunction (ED). Considering recent evidence that tumor necrosis factor-α (TNF-α) levels are increased in serum of patients with ED, the present study investigated the effects of infliximab (a TNF-α blocker) on endothelial nitric oxide synthase (eNOS) and neuronal NOS (nNOS) immunoreactivity of rat penile corpus cavernosum in unpredictable chronic mild stress (UCMS). Male adult rats were randomly divided into three groups (n=8 per group): Control, UCMS and UCMS+infliximab...
December 1, 2016: International Journal of Impotence Research
https://www.readbyqxmd.com/read/27894157/brief-report-relationship-between-serum-infliximab-concentrations-and-risk-of-infections-in-patients-treated-for-spondyloarthritis
#8
Theodora Bejan-Angoulvant, David Ternant, Fadela Daoued, Frédéric Medina, Louis Bernard, Saloua Mammou, Gilles Paintaud, Denis Mulleman
OBJECTIVE: Tumor necrosis factor inhibitors are effective in reducing inflammation in rheumatic diseases but increase the risk of infections. This study was undertaken to investigate the relationship between the trough serum concentration of infliximab (IFX) and the risk of a first infection episode. METHODS: We retrospectively included all patients who started IFX treatment for an approved indication in our department. Patients were followed up based on recommended IFX infusion schedules...
January 2017: Arthritis & Rheumatology
https://www.readbyqxmd.com/read/27882586/efficacy-and-safety-of-dose-escalation-of-infliximab-therapy-in-japanese-patients-with-psoriasis-results-of-the-spread-study
#9
Hideshi Torii, Masayuki Nakano, Toshiro Yano, Kazuoki Kondo, Hidemi Nakagawa
Although infliximab is approved for psoriasis, its efficacy is reduced over time in some patients. The aim of this phase III trial is to evaluate efficacy and safety of infliximab dose escalation in Japanese psoriasis patients with loss of efficacy to standard-dose therapy. Patients with plaque psoriasis, psoriatic arthritis, pustular psoriasis or psoriatic erythroderma who showed loss of efficacy to standard-dose therapy received infliximab dose escalation (10 mg/kg every 8 weeks) from weeks 0 to 32. Loss of efficacy was defined as not maintaining 50% reduction in the Psoriasis Area and Severity Index (PASI 50) after achieving PASI 75...
November 24, 2016: Journal of Dermatology
https://www.readbyqxmd.com/read/27873119/validation-of-a-drug-resistant-anti-adalimumab-antibody-assay-to-monitor-immunogenicity-in-the-presence-of-high-concentrations-of-adalimumab
#10
Sumin Bian, Marc Ferrante, Ann Gils
With respect to patient safety and long-term efficacy, immunogenicity of therapeutic antibodies remains an important issue. Pre-treatment of samples using either higher temperature or acidification in order to separate drug/anti-drug antibody complexes has been implemented in the traditional bridging assay and an in-house-developed affinity capture elution assay but only a limited drug tolerance was obtained. In this study, we aim to apply a drug-resistant anti-drug antibody assay to adalimumab through a combination of adalimumab/anti-adalimumab antibody complex precipitation and acid dissociation...
November 21, 2016: AAPS Journal
https://www.readbyqxmd.com/read/27853420/reducing-peripheral-inflammation-with-infliximab-reduces-neuroinflammation-and-improves-cognition-in-rats-with-hepatic-encephalopathy
#11
Sherry Dadsetan, Tiziano Balzano, Jerónimo Forteza, Andrea Cabrera-Pastor, Lucas Taoro-Gonzalez, Vicente Hernandez-Rabaza, Sara Gil-Perotín, Laura Cubas-Núñez, José-Manuel García-Verdugo, Ana Agusti, Marta Llansola, Vicente Felipo
Inflammation contributes to cognitive impairment in patients with hepatic encephalopathy (HE). However, the process by which peripheral inflammation results in cognitive impairment remains unclear. In animal models, neuroinflammation and altered neurotransmission mediate cognitive impairment. Taking into account these data, we hypothesized that in rats with HE: (1) peripheral inflammation is a main contributor to neuroinflammation; (2) neuroinflammation in hippocampus impairs spatial learning by altering AMPA and/or NMDA receptors membrane expression; (3) reducing peripheral inflammation with infliximab (anti-TNF-a) would improve spatial learning; (4) this would be associated with reduced neuroinflammation and normalization of the membrane expression of glutamate receptors...
2016: Frontiers in Molecular Neuroscience
https://www.readbyqxmd.com/read/27845027/clinical-effectiveness-and-cost-effectiveness-of-use-of-therapeutic-monitoring-of-tumour-necrosis-factor-alpha-tnf-%C3%AE-inhibitors-lisa-tracker%C3%A2-enzyme-linked-immunosorbent-assay-elisa-kits-tnf-%C3%AE-blocker-elisa-kits-and-promonitor%C3%A2-elisa-kits-versus-standard-care
#12
Karoline Freeman, Martin Connock, Peter Auguste, Sian Taylor-Phillips, Hema Mistry, Deepson Shyangdan, Rachel Court, Ramesh Arasaradnam, Paul Sutcliffe, Aileen Clarke
BACKGROUND AND OBJECTIVES: Systematic reviews and economic modelling of clinical effectiveness and cost-effectiveness of therapeutic monitoring of tumour necrosis factor alpha (TNF-α) inhibitors [using LISA-TRACKER(®) enzyme-linked immunosorbent assay (ELISA) kits (Theradiag, Marne La Vallee, France, or Alpha Laboratories, Heriot, UK), TNF-α-Blocker ELISA kits (Immundiagnostik AG, Bensheim, Germany) and Promonitor(®) ELISA kits (Proteomika, Progenika Biopharma, Bizkaia, Spain)] versus standard care for Crohn's disease (CD)...
November 2016: Health Technology Assessment: HTA
https://www.readbyqxmd.com/read/27821943/green-tea-and-exercise-interventions-as-nondrug-remedies-in-geriatric-patients-with-rheumatoid-arthritis
#13
Ahmad H Alghadir, Sami A Gabr, Einas S Al-Eisa
This study aimed to evaluate the effects of green tea and supervised exercise training interventions on improvement of disease activity and bone metabolism markers in rheumatoid arthritis patients. [Subjects and Methods] One-hundred and twenty subjects who had a mean age of (60.7 ± 2.53 years) and had been diagnosed with rheumatoid arthritis at least ten years previously were randomly included in this study. Patients were treated with infliximab, green tea, or a supervised exercise program for six months...
October 2016: Journal of Physical Therapy Science
https://www.readbyqxmd.com/read/27800198/a-case-report-of-neurosarcoidosis-presenting-as-a-lymphoma-mimic
#14
Gurcharanjeet Kaur, Lauren Cameron, Olga Syritsyna, Patricia Coyle, Agnes Kowalska
Objective. To describe a unique presentation of neurosarcoidosis. Background. Central nervous system involvement is rare in sarcoidosis. Sarcoidosis can be severe and can be mistaken for systemic lymphoma. Case Description. A 55-year-old right-handed white male with past medical history of obstructive sleep apnea, Raynaud's disease, and Hashimoto's thyroiditis was noted to have cognitive decline over a duration of few weeks and 20 lb weight loss. His neurologic exam (including cranial nerves) was normal except for five-minute recall...
2016: Case Reports in Neurological Medicine
https://www.readbyqxmd.com/read/27781498/infliximab-therapy-reverses-the-increase-of-allograft-inflammatory-factor-1-in-serum-and-colonic-mucosa-of-rats-with-inflammatory-bowel-disease
#15
Irene D Román, David Cano-Martínez, María Val T Lobo, María Dolores Fernández-Moreno, Borja Hernández-Breijo, Silvia Sacristán, Patricia Sanmartín-Salinas, Jorge Monserrat, Javier P Gisbert, Luis G Guijarro
: Objetive: Our purpose was to study the molecular basis of infliximab (IFX) effect on colon mucosa in a colitis model and to identify new biomarkers of mucosal healing. METHODS: Healthy rats and rats which were subjected to experimental colitis induced by dextran sulphate sodium, with or without IFX treatment (in the short- and long-term), were studied along with forty-seven IBD patients. Colon mucosal integrity by Periodic Acid Schiff staining, intestinal damage by immunohistochemistry (proliferating cell nuclear antigen, β-catenin, E-cadherin, phosphotyrosine, p-p38, allograft inflammatory factor-1 (AIF-1) and colonic mucosal apoptosis by TUNEL staining were evaluated in rats...
October 26, 2016: Biomarkers: Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals
https://www.readbyqxmd.com/read/27778459/infliximab-is-equivalently-suppressing-oxidative-stress-compared-to-tocilizumab-among-well-controlled-patients-with-rheumatoid-arthritis
#16
Kazuha Kizaki, Fumiharu Yamashita, Tomoya Hayashi, Noboru Funakoshi
AIM: This study was designed to investigate which biological agent, infliximab or tocilizumab, would more intensively keep suppressing oxidative stress among well-controlled patients as C-reactive protein (CRP) levels normalized in rheumatoid arthritis (RA). In addition, it was intended to clarify indicative factors of oxidative stress among well-controlled patients with RA. METHODS: We recruited 61 well-controlled (CRP < 0.3 mg/dL within normal ranges) patients with RA using biological agents (infliximab n = 33; tocilizumab n = 28), active RA patients with CRP > 1...
October 24, 2016: International Journal of Rheumatic Diseases
https://www.readbyqxmd.com/read/27762509/analytical-and-clinical-evaluation-of-an-immunoassay-for-estimating-immunogenicity-of-infliximab-and-etanercept-in-indian-population
#17
Canna Ghia, Shashank Akerkar, Shailaja Sabnis, Urk Rao, Gautam Rambhad
BACKGROUND / OBJECTIVES: Biologic anti-TNFs in India have improved the patient management. Significant proportions of patients lose response over time or do not respond. Possible explanations are suboptimal trough anti-TNFa concentrations or antibodies to anti-TNFs. The aim of this project was to set up and standardize an independent laboratory to test immunogenicity of anti-TNF biologics (infliximab and etanercept). METHODS: Three rheumatologists piloted this project approved by independent ethics committee and carried out in compliance with ICH/GCP guidelines...
September 2016: Journal of the Association of Physicians of India
https://www.readbyqxmd.com/read/27747509/early-prognostic-factors-associated-with-the-efficacy-of-infliximab-treatment-for-patients-with-rheumatoid-arthritis-with-inadequate-response-to-methotrexate
#18
Satoko Hayashi, Katsuya Suzuki, Keiko Yoshimoto, Masaru Takeshita, Takahiko Kurasawa, Kunihiro Yamaoka, Tsutomu Takeuchi
INTRODUCTION: Early prognostic factors for the clinical response in patients with rheumatoid arthritis (RA) after 1 year of treatment with infliximab (IFX) as part of routine clinical practice were investigated. METHODS: Thirty-five patients with RA with an inadequate response to methotrexate were enrolled and administered IFX (3-9 mg/kg, every 4-8 weeks). Serum trough levels of IFX and levels of 9 cytokines were measured at baseline and at 3, 6 months, and 1 year...
June 2016: Rheumatology and Therapy
https://www.readbyqxmd.com/read/27739008/pharmacokinetic-dashboard-recommended-dosing-is-different-than-standard-of-care-dosing-in-infliximab-treated-pediatric-ibd-patients
#19
Marla C Dubinsky, Becky L Phan, Namita Singh, Shervin Rabizadeh, Diane R Mould
Standard of care (SOC; combination of 5-10 mg/kg and an interval every 6-8 weeks) dosing of infliximab (IFX) is associated with significant loss of response. Dashboards using covariates that influence IFX pharmacokinetics (PK) may be a more precise way of optimizing anti-TNF dosing. We tested a prototype dashboard to compare forecasted dosing regimens with actual administered regimens and SOC. Fifty IBD patients completing IFX induction were monitored during maintenance (weeks 14-54). Clinical and laboratory data were collected at each infusion; serum was analyzed for IFX concentrations and anti-drug antibodies (ADA) at weeks 14 and 54 (Prometheus Labs, San Diego)...
January 2017: AAPS Journal
https://www.readbyqxmd.com/read/27702827/association-of-induction-infliximab-levels-with-clinical-response-in-perianal-crohn-s-disease
#20
Yana Davidov, Bella Ungar, Haggai Bar-Yoseph, Dan Carter, Ola Haj-Natour, Miri Yavzori, Yehuda Chowers, Rami Eliakim, Shomron Ben-Horin, Uri Kopylov
BACKGROUND: The association of infliximab [IFX] trough levels with clinical and endoscopic outcomes in inflammatory bowel disease is well established. However, there is scarce data regarding the association of perianal fistula response with IFX. The aim of this study was to establish whether early induction infliximab levels and anti-infliximab antibodies [ATIs] are associated with perianal fistula response. METHODS: Consecutive CD patients with perianal fistulae that were treated with IFX between 2008 and 2016 were included in the study...
October 4, 2016: Journal of Crohn's & Colitis
keyword
keyword
43807
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"